Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Unremarkable impact of Oatp inhibition on the liver concentration of fluvastatin, lovastatin and pitavastatin in wild-type and Oatp1a/1b knockout mouse.

Chang JH, Zhang X, Messick K, Chen YC, Chen E, Cheong J, Ly J.

Xenobiotica. 2019 May;49(5):602-610. doi: 10.1080/00498254.2018.1478167. Epub 2018 Jun 6.

PMID:
29768081
2.

Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions.

Ly JQ, Messick K, Qin A, Takahashi RH, Choo EF.

Mol Pharm. 2017 May 1;14(5):1754-1759. doi: 10.1021/acs.molpharmaceut.7b00006. Epub 2017 Apr 7.

PMID:
28345929
3.

Balancing Blood Sample Volume with 3Rs: Implementation and Best Practices for Small Molecule Toxicokinetic Assessments in Rats.

Harstad E, Andaya R, Couch J, Ding X, Liang X, Liederer BM, Messick K, Nguyen T, Schweiger M, Tarrant J, Zhong S, Dean B.

ILAR J. 2016 Dec;57(2):157-165. doi: 10.1093/ilar/ilw023. Review.

PMID:
28053069
4.

Rifampin-Mediated Induction of Tamoxifen Metabolism in a Humanized PXR-CAR-CYP3A4/3A7-CYP2D6 Mouse Model.

Chang JH, Chen J, Liu L, Messick K, Ly J.

Drug Metab Dispos. 2016 Nov;44(11):1736-1741. Epub 2016 Aug 18.

PMID:
27538915
5.

Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat.

Fan PW, Chen JZ, Allan Jaochico M, La H, Liu N, Mulder T, Cass RT, Durk M, Messick K, Valle N, Liu S, Lee W, Crawford JJ, Rudolf J, Murray LJ, Cyrus Khojasteh S, Wright M.

Drug Metab Lett. 2016;10(2):91-100.

6.

Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.

Choo EF, Woolsey S, DeMent K, Ly J, Messick K, Qin A, Takahashi R.

Drug Metab Dispos. 2015 Jun;43(6):864-9. doi: 10.1124/dmd.115.063743. Epub 2015 Mar 26.

PMID:
25813936
7.

Prediction of drug distribution in subcutaneous xenografts of human tumor cell lines and healthy tissues in mouse: application of the tissue composition-based model to antineoplastic drugs.

Poulin P, Chen YH, Ding X, Gould SE, Hop CE, Messick K, Oeh J, Liederer BM.

J Pharm Sci. 2015 Apr;104(4):1508-21. doi: 10.1002/jps.24336. Epub 2015 Jan 14.

PMID:
25615572
8.

Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.

Choo EF, Ly J, Chan J, Shahidi-Latham SK, Messick K, Plise E, Quiason CM, Yang L.

Mol Pharm. 2014 Nov 3;11(11):4199-207. doi: 10.1021/mp500435s. Epub 2014 Oct 3.

PMID:
25243894
9.

Measuring NAD(+) levels in mouse blood and tissue samples via a surrogate matrix approach using LC-MS/MS.

Liang X, Yang L, Qin AR, Ly J, Liederer BM, Messick K, Ma S, Zak M, Dragovich PS, Dean BJ, Hop CE, Deng Y.

Bioanalysis. 2014 Jun;6(11):1445-57. doi: 10.4155/bio.14.8. Erratum in: Bioanalysis. 2014;6(13):1870.

PMID:
25046046
10.

Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice.

Chang JH, Ly J, Plise E, Zhang X, Messick K, Wright M, Cheong J.

Drug Metab Dispos. 2014 Jun;42(6):1067-73. doi: 10.1124/dmd.114.057968. Epub 2014 Mar 26.

PMID:
24671957
11.

Assessment of the hepatic CYP reductase null mouse model and its potential application in drug discovery.

Boggs JW, Hop CE, McNamara E, Deng Y, Messick K, West K, Choo EF.

Mol Pharm. 2014 Mar 3;11(3):1062-8. doi: 10.1021/mp400556x. Epub 2014 Jan 29.

PMID:
24450768
12.

Investigations into the mechanisms of pyridine ring cleavage in vismodegib.

Khojasteh SC, Yue Q, Ma S, Castanedo G, Chen JZ, Lyssikatos J, Mulder T, Takahashi R, Ly J, Messick K, Jia W, Liu L, Hop CE, Wong H.

Drug Metab Dispos. 2014 Mar;42(3):343-51. doi: 10.1124/dmd.113.055715. Epub 2014 Jan 3.

PMID:
24389420
13.

Solvent-based formulations for intravenous mouse pharmacokinetic studies: tolerability and recommended solvent dose limits.

Thackaberry EA, Wang X, Schweiger M, Messick K, Valle N, Dean B, Sambrone A, Bowman T, Xie M.

Xenobiotica. 2014 Mar;44(3):235-41. doi: 10.3109/00498254.2013.845706. Epub 2013 Oct 18.

PMID:
24138296
14.

Vacuum-mixing cement does not decrease overall porosity in cemented femoral stems: an in vitro laboratory investigation.

Messick KJ, Miller MA, Damron LA, Race A, Clarke MT, Mann KA.

J Bone Joint Surg Br. 2007 Aug;89(8):1115-21.

15.

Increased risk of posterior glenoid labrum tears in football players.

Escobedo EM, Richardson ML, Schulz YB, Hunter JC, Green JR 3rd, Messick KJ.

AJR Am J Roentgenol. 2007 Jan;188(1):193-7.

PMID:
17179364
16.
17.

Gross boron determination in biological samples by inductively coupled plasma-atomic emission spectroscopy.

Bauer WF, Johnson DA, Steele SM, Messick K, Miller DL, Propp WA.

Strahlenther Onkol. 1989 Feb-Mar;165(2-3):176-9. No abstract available.

PMID:
2928943
18.

Alpha-2-adrenoceptor-mediated effects of pergolide.

Ruffolo RR Jr, Cohen ML, Messick K, Horng JS.

Pharmacology. 1987;35(3):148-54.

PMID:
2825224
19.
20.

Inotropic selectivity of dobutamine enantiomers in the pithed rat.

Ruffolo RR Jr, Messick K.

J Pharmacol Exp Ther. 1985 Nov;235(2):344-8.

PMID:
4057075
21.

Interactions of the enantiomers of 3-O-methyldobutamine with alpha- and beta-adrenoceptors in vitro.

Ruffolo RR Jr, Messick K, Horng JS.

Naunyn Schmiedebergs Arch Pharmacol. 1985 May;329(3):244-52.

PMID:
2991776
22.

Interactions of dimethoxy-substituted tolazoline derivatives with alpha 1- and alpha 2-adrenoreceptors in vitro.

Ruffolo RR Jr, Messick K, Horng JS.

J Auton Pharmacol. 1985 Mar;5(1):71-9.

PMID:
2859291
23.
26.

The 3,4-catechol derivative of propranolol, a minor dihydroxylated metabolite.

Nelson WL, Bartels MJ, Bednarski PJ, Zhang S, Messick K, Horng JS, Ruffolo RR Jr.

J Med Chem. 1984 Jul;27(7):857-61.

PMID:
6330358
27.

Interactions of three inotropic agents, ASL-7022, dobutamine and dopamine, with alpha- and beta-adrenoceptors in vitro.

Ruffolo RR Jr, Messick K, Horng JS.

Naunyn Schmiedebergs Arch Pharmacol. 1984 Jul;326(4):317-26.

PMID:
6090958

Supplemental Content

Loading ...
Support Center